Olympus (7733.T) lost roughly ¥300 billion in market value in a single Tokyo session.
The Japanese medical-device maker closed Wednesday at ¥1,756, down ¥276.5 or 13.6% from Tuesday's ¥2,032.5 finish. It opened at ¥1,782.5 and sank to a ¥1,697 intraday low — 16.5% under the previous close. At the low the loss touched about 17%, the worst one-day drop since April 2025.
The trigger was an FDA warning letter dated October 7, disclosed in a company filing on Tuesday. The letter says Olympus's replies to agency violations found last year — documented in 2025 Form 483 reports after inspections at six facilities — were inadequate. Crucially, the warning imposes no ban on producing or selling devices, orders no recalls, and blocks no new clearances. Olympus says it already proposed corrective measures, will file its FDA response this month, and must answer formally within 15 business days. The letter is not on the FDA's public database yet.
The inspected sites include endoscope plants and offices in Japan, the Olympus Winter & Ibe unit in Hamburg, and Gyrus ACMI in Minnesota — the surgical-instrument maker Olympus bought in 2008. CEO Bob White said the firm takes the findings seriously and will resolve them "with urgency and rigor." Olympus also told investors it sees no hit to consolidated results.
Why it matters
Investors are pricing in something the company says is not there. A warning letter with no ban, no recall and no financial impact should normally fade in two days. Instead Olympus shed nearly ¥300 billion — about $1.9 billion at ¥158 to the dollar — off a ¥2.19 trillion market cap. The panic makes sense only with context: this is the latest chapter in a long regulatory overhang. Olympus has collected multiple FDA warning letters tied to endoscope manufacturing. The agency placed import alerts on Japan-made laparoscopes and endoscope reprocessors in mid-2025. A January recall of three high-flow insufflation models was classed as Class I — the FDA's most serious — after two injuries. The stock was already fragile: down 11.6% over the past month and 11.5% this year, trading at about 28 times trailing EPS of ¥61.32. Wednesday's move joins Asia's recent run of sharp single-stock shocks, like SK Hynix and Samsung's sell-off on a Chinese chip breakthrough. See our stocks coverage for the next tape shock.
What to watch
- The 15-business-day response — whether Olympus's corrective plan convinces the agency is the key swing factor.
- FDA database posting — the letter is not public yet; its release could trigger a second wave of headlines.
- Import-alert escalation — the mid-2025 alerts on laparoscopes and reprocessors are the precedent; any expansion carries real revenue risk.
- Nov 6 earnings — the next results report lands weeks away and will be the first formal Q&A on the letter.
- ¥1,697 and ¥2,032.5 — Wednesday's low versus Tuesday's close frame the near-term battle; consensus still rates the stock a Buy with a ¥3,300 target.
MarketRadar take
The tape and the press release disagree. Olympus says "no impact"; the market erased 13.6% of the equity value. One side is wrong. Either the 15-day response reassures investors and the stock retraces toward ¥2,032.5, or the letter's public release justifies the panic. We lean bearish near-term: the overhang is cumulative, and a stock already down 11.5% this year has no goodwill left. Watch ¥1,697. A second test that holds would mark the start of a bottom. A break opens the way toward ¥1,600 — and below that, the 52-week low at ¥1,302.5.
| Level | Price (¥) | Signal |
|---|---|---|
| Oct 13 close | 2,032.5 | broken support, now resistance |
| Oct 14 open | 1,782.5 | 12.3% gap down |
| Oct 14 intraday low | 1,697 | near-term support to hold |
| 52-week low | 1,302.5 | deep downside reference |
| Consensus target | 3,300 | Buy-rated upside case |
